Race Oncology (ASX: RAC) Launches Lung Cancer Program: Buy the Breakout or Wait for a Pullback?
Race Oncology (ASX: RAC) unveiled two new clinical programs, expanding its lead drug RC220 into acute myeloid leukaemia and EGFR-mutated non-small cell lung cancer. For investors tracking the Australian biotech space, this announcement represents a significant strategic shift. Race is now targeting one of oncology's largest markets, where treatment resistance remains a critical challenge. The…
Is Pro Medicus Still a Buy at 150x Earnings? What the Valuation Means for Investors
Pro Medicus (ASX: PME) trades at a valuation that defies conventional wisdom. Despite a 25% pullback from July's $336 peak to around $250, the healthcare imaging software company still commands a price-to-earnings ratio exceeding 260 times trailing earnings. Yet the stock remains up more than 60% over the past year, driven by a record contract…
AMA Group Insider Buys 2 Million Shares at 10 Cents: Distressed Opportunity or Value Trap?
AMA Group (ASX: AMA) director Brian Austin just bought another 2 million shares at 10 cents apiece, his third substantial purchase in three months. This latest November transaction follows aggressive buying in August, bringing his total investment to over $700,000 at current distressed levels. For investors watching the collision repair sector, this raises a critical…
Matt Tripp Doubles Down on Bet
Why Matt Tripp Is Doubling Down on Betr After Losing the $400M PointsBet Battle
Betr Entertainment (ASX: BBT) lost the brutal battle for PointsBet in September 2025, with Japan's MIXI securing 51.86% control through a superior cash offer. But instead of retreating, founder Matt Tripp appears to be doubling down. Reports from August 2025 indicate Tripp held meetings with Entain executives in London to discuss acquiring their Australian operations,…
Aristocrat Leisure Falls Despite Strong FY25 Results: Is the Market Wrong About This Gaming Giant?
Aristocrat Leisure (ASX: ALL) shares fell 3.4% to $62.10 on results day and have since drifted to around $59, despite the gaming giant delivering a solid FY25 performance that beat market expectations. The company reported normalised net profit of $1.55 billion, up 12%, with revenue climbing 11% to $6.30 billion and EBITDA surging 15.6% to…
Xero Falls 5% Despite Beating Expectations: Why Strong Results Don’t Always Mean Higher Prices
Xero (ASX: XRO) delivered results on November 13 that beat analyst expectations across the board, yet shares fell 5% in response. Revenue climbed 20% to NZ$1,194 million, EBITDA came in at NZ$377.9 million, well ahead of Macquarie's NZ$344 million forecast, and free cash flow margins continued expanding. For most companies, this would trigger a rally.…
© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here